January 1, 1997Journal of Hypertension
Pharmacology of the calcium antagonist mibefradil
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support T-type blockade for vasodilation without inotropy concerns; leaves open confirmation in randomized outcome trials.
Structured PICO
I
Intervention
Mibefradil
Mibefradil represents a new class of calcium channel blockers (T-type) with a favorable hemodynamic and side-effect profile compared to traditional agents.
Cite This Study
Lüscher et al. (1997) studied this question.